Metabolism and Disposition of Dasatinib after Oral Administration to Humans-Reference-Cited by-同舟云学术

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Published:2008-04-17 Issue:7 Volume:36 Page:1357-1364
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Christopher Lisa J.,Cui Donghui,Wu Chiyuan,Luo Roger,Manning James A.,Bonacorsi Samuel J.,Lago Michael,Allentoff Alban,Lee Francis Y. F.,McCann Betty,Galbraith Susan,Reitberg Donald P.,He Kan,Barros Anthony,Blackwood-Chirchir Anne,Humphreys W. Griffith,Iyer Ramaswamy A.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference20 articles.

1. Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys

2. 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics of Dasatinib in Healthy Subjects;Pharmaceuticals;2024-05-23

2. A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions;CPT: Pharmacometrics & Systems Pharmacology;2024-05

3. Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice;Mechanisms of Ageing and Development;2024-04

4. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia;Cureus;2024-03-20

5. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03